McKesson Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

McKesson (MCK) Stock Could Be 17.3% Undervalued After Loan Deal And Buybacks - simplywall.st

AI-generated analysis

📊 McKesson is currently trading at $785.43, representing a 17.3% discount to a calculated fair value of $949.73.

💰 The company recently secured a US$2.25 billion senior secured term loan with a maturity date in 2032.

📉 Recent stock performance shows a 14.66% decline over the last 90 days and a 4.62% drop year-to-date.

🔄 McKesson is actively executing share repurchases to support shareholder value despite recent market cooling.

🏥 The company sold a minority stake in its Medical-Surgical Solutions division as part of portfolio reshaping.

📈 Long-term holders have been rewarded with an 8.87% total return over the last year and strong five-year performance.

🛠️ McKesson is expanding value-added services including pharmacy management and patient access solutions to improve revenue visibility.

⚖️ Current P/E ratio of 19.3x is significantly lower than the US Healthcare industry average of 23.2x and peer average of 23.9x.

🔮 Valuation models assume McKesson will continue compounding scale advantages to drive steady top-line expansion.

⚠️ Key risks include potential margin compression from tighter drug price regulations and payers reducing reliance on wholesalers.

Bullish Signals
  • McKesson is trading at a significant discount with a fair value of $949.73 compared to the current price of $785.43, suggesting a 17.3% undervaluation.
  • The company has secured substantial financing via a US$2.25 billion term loan, providing capital for growth and operations without immediate dilution pressure.
  • Ongoing share repurchases demonstrate management's commitment to returning capital to shareholders and supporting the stock price.
  • McKesson holds a P/E ratio of 19.3x, which is well below the industry average of 23.2x and peer average of 23.9x, indicating a potential value opportunity.
  • The company's long-term track record remains strong with an 8.87% one-year total shareholder return despite recent short-term volatility.
  • Expansion into high-value services like pharmacy management and patient adherence solutions creates recurring revenue streams and improves margin visibility.
Risk Factors
  • Recent stock performance has been weak, with a 14.66% decline over the last 90 days and a 4.62% drop year-to-date.
  • The company faces potential margin pressure if tighter drug price regulations are implemented in the future.
  • There is a risk that vertically integrated payers and pharmacy benefit managers (PBMs) may reduce their reliance on traditional wholesalers like McKesson.
Full Analysis
McKesson (MCK) stock is currently trading at $785.43, which a valuation model suggests is undervalued by approximately 17.3% relative to a calculated fair value of $949.73. This assessment follows recent corporate developments including a US$2.25 billion senior secured term loan maturing in 2032, a minority sale within its Medical-Surgical Solutions division, and ongoing share repurchase programs. Despite a recent pullback that has resulted in a 14.66% decline over the last 90 days and a 4.62% drop year-to-date, McKesson maintains a positive long-term track record with an 8.87% one-year total shareholder return and a substantial five-year history of rewards for investors. The company's strategy focuses on expanding value-added services such as pharmacy management and patient adherence solutions to build recurring revenue streams. The bullish narrative relies on McKesson's ability to leverage its scale advantages in an increasingly complex pharmaceutical supply chain, which includes challenges like biosimilars and cold chain logistics. Analysts believe these factors contribute to competitive market share gains and margin expansion, though the stock faces potential headwinds from tighter drug price regulations and reduced reliance on wholesalers by vertically integrated payers.